Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759]

[1]  L. Traverso,et al.  The Virginia Mason approach to localized pancreatic cancer. , 2004, Surgical oncology clinics of North America.

[2]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[3]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[4]  L. Traverso,et al.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2003, American journal of surgery.

[5]  John M. Kirkwood,et al.  Cancer immunotherapy: The interferon-α experience , 2002 .

[6]  C. Kerr.  Adjuvant interferon-α improves skin cancer survival , 2002 .

[7]  R. Dillman,et al.  Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10. , 2002, Cancer biotherapy & radiopharmaceuticals.

[8]  B. Zhivotovsky,et al.  Mechanisms of Interferon-alpha induced apoptosis in malignant cells , 2002, Oncogene.

[9]  P. Nathan,et al.  The biological treatment of renal-cell carcinoma and melanoma. , 2002, The Lancet. Oncology.

[10]  D. Kerr,et al.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial , 2001, The Lancet.

[11]  D. Grandér,et al.  Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. , 2000, Blood.

[12]  H J Kolb,et al.  Interferon alpha in combination with GM‐CSF induces the differentiation of leukaemic antigen‐presenting cells that have the capacity to stimulate a specific anti‐leukaemic cytotoxic T‐cell response from patients with chronic myeloid leukaemia , 2000, British journal of haematology.

[13]  H. Kolb,et al.  Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. , 2000 .

[14]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[15]  J. Lee,et al.  Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  H. Eguchi,et al.  Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  D. Grandér.  How Does Interferon-Alpha Exert Its Antitumour Activity in Multiple Myeloma? , 2000, Acta oncologica.

[18]  H. Friess,et al.  Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. , 1999, European journal of cancer.

[19]  J. Verweij,et al.  Immunotherapy of metastatic renal cell cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Fosså,et al.  Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P F Thall,et al.  Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.

[22]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[23]  R. Pazdur.  Fluorouracil and recombinant interferon alfa‐2a in advanced gastrointestinal neoplasms , 1991, British journal of haematology.

[24]  F. Demard,et al.  Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. , 1991, British Journal of Cancer.

[25]  J. Ajani,et al.  Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Cantell,et al.  Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. , 1987, International journal of radiation oncology, biology, physics.

[27]  L. Radloff.  The CES-D Scale , 1977 .

[28]  C. Kerr.  Adjuvant interferon-alpha improves skin cancer survival. , 2002, The Lancet. Oncology.

[29]  John Kirkwood,et al.  Cancer immunotherapy: the interferon-alpha experience. , 2002, Seminars in oncology.